JPRN-UMIN000012454招募中未知
PegIFNalpha-2a treatment added-on entecavir for HBeAg and HBV DNA negative patients treated with long-term entecavir - PegIFNalpha-2a treatment added-on entecavir
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients receiving Chinese herb (sho-sai-ko-to) 2) Patients with history of interstitial pneumonia 3) Patients with auto immune hepatitis 4) Patients with hypersensitivity to interferon 5) Patients with hypersensitivity to biological agents 6) Patients with neutropenia (<1500/mm3), thrombocytopenia (<90000/mm3), or anemia (Hb<12g/dL) 7) Cirrhotic patients 8) Patients with history of HCC 9) Doctors consider inadequate
研究者
相似试验
招募中
不适用
Peg-IFN-alfa 2b/Ribavirin/Vaniprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and duration of therapychronic hepatitis CJPRN-UMIN000016639Kanazawa University100
招募中
不适用
Peg-IFN-alfa2b/Ribavirin/Telaprevir therapy for chronic hepatitis C: Effectiveness prediction by gene analysis and Duration of therapyJPRN-UMIN000008198Kanazawa University200
Unknown
4 期
Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis BHepatitis B, ChronicNCT00917761National Taiwan University Hospital300
Unknown
4 期
Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis BHepatitis B, ChronicNCT00921180National Taiwan University Hospital148
已完成
不适用
The combination therapy of PEG-IFN alpha 2b, Ribavirin and Telaprevir for the patients with chronic hepatitis C:the study for treatment duration by response guided therapy and prediction of efficacy by gene analysis in Japan.chronic hepatitis CJPRN-UMIN000018971agoya university500